Some 300 biotech executives and industry leaders are objecting to the decision from a Texas federal judge to block the FDA’s approval of abortion drug mifepristone. The executives argue that the judicial interference will undermine the agency’s authority and endanger innovation in the industry.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,